Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96L93
UPID:
KI16B_HUMAN
Alternative names:
Sorting nexin-23
Alternative UPACC:
Q96L93; A6NKJ9; A7E2A8; B1AKG3; B1AKT7; C9JDN5; C9JI52; C9JSM8; C9JWJ7; Q2TBF5; Q5HYC0; Q5HYK1; Q5JWW3; Q5TFK5; Q86VL9; Q86YS5; Q8IYU0; Q9BQJ8; Q9BQM0; Q9BQM1; Q9BQM5; Q9H5U0; Q9HCI2; Q9NXN9
Background:
Kinesin-like protein KIF16B, also known as Sorting nexin-23, plays a crucial role in cellular dynamics, specifically in endosome transport and receptor recycling and degradation. It is a plus end-directed microtubule-dependent motor protein that ensures the proper balance between recycling and degradation of critical receptors such as EGF receptor (EGFR) and FGF receptor (FGFR). KIF16B's regulation of the Golgi to endosome transport of FGFR-containing vesicles is vital for early postimplantation development.
Therapeutic significance:
Understanding the role of Kinesin-like protein KIF16B could open doors to potential therapeutic strategies. Its pivotal function in receptor trafficking and cellular transport mechanisms positions it as a key target for modulating cellular processes involved in various diseases.